Apoptosis: Market Research Report

September 2011 | 617 pages | ID: P1FC376CC89EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Apoptosis in US$ Million.

The report provides separate comprehensive analytics for the US, Canada, Europe, Asia Pacific, Latin America, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for these markets.

The report profiles 114 companies including many key and niche players such as Abbott Laboratories, AbGenomics International, Inc., Aegera Therapeutics, Inc., Amgen, Inc., Anavex Life Sciences Corporation, ApopLogic Pharmaceuticals Inc., Ascenta Therapeutics, ArQule, Inc., Bioniche Life Sciences, Inc., Celgene Corporation, Chroma Therapeutics Ltd., Cancer Research Technology Ltd., EntreMed, Inc., EpiCept Corporation, Exelixis Inc., Genextra S.p.A, Genta, Inc., Infinity Pharmaceuticals Inc., ISIS Pharmaceutical Inc., Novartis Ltd., Pfizer, Inc., Pharmacyclics, Inc., S*BIO Pte Ltd., S*BIO Pte Ltd, TopoTarget A/S, Xigen SA, and ?terna Zentaris GmbH.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

2.INDUSTRY OVERVIEW

Apoptosis: A Natural Part of Cell Lifecycle
The Cell Death Pathway: A Review
Apoptosis Modulating Drugs All Set for Commercial Stage Competition

Table 1. Apoptosis Drugs Pipeline Scenario Worldwide (2008): Percentage Share Breakdown of Number of Apoptosis Modulating Drugs in Development by Development Stage (includes corresponding Graph/Chart)

R&D Scenario

Table 2. Apoptosis R&D Scenario Worldwide (2010): Percentage Share Breakdown of Number of Apoptosis Modulating Drugs in Development by Treatment Area (includes corresponding Graph/Chart)

Table 3. Apoptosis Drug Development Worldwide (2010): Percentage Share Breakdown of Number of Apoptosis Modulating Drugs in Development by Agent Type (includes corresponding Graph/Chart)

Table 4. Top Nations for Apoptosis Research (2011): Breakdown of Number of Researchers Involved in Apoptosis Research by Country (includes corresponding Graph/Chart)

Popular Classes of Molecules Influencing the Apoptotic Process: A Review
Noteworthy Molecular Targets for Apoptosis
Death Receptors
Caspases
IAPs and SMAC
Bcl-2 proteins
p53

Table 5. Apoptosis Drugs Pipeline Worldwide (2010): Percentage Share Breakdown of Number of Apoptosis Modulating Agents in Development by Molecular Target

HSP90: A Popular Gene Target for Apoptosis
Apoptosis: The Key to Cutting Edge Cancer Treatment/Therapies

Table 6. Apoptosis R&D in Cancer Treatment (2010): Percentage Share Breakdown of Number of Apoptosis Modulating Drugs in Development by Type of Cancer (includes corresponding Graph/Chart)

Focus on Targeted Therapy Bodes Well for Apoptosis-Targeted Therapies for Cancer
Overcoming Therapy/Drug Resistance: A Major Business Case for Direct Apoptogens
Factors Encouraging Investments in Apoptosis Based Cancer Drugs
Rise in Cancer Incidences Fosters Growth in Cancer Related Apoptosis Research
Low Entry Barriers in Cancer Research Encourages Cancer Related Apoptosis Research
Government Funded Investments Bode Well for Cancer Related Apoptosis Research
High Prices/Efficacy Encourage Pharmas in Pushing Commercialization of Apoptosis-Based Anticancer Drugs
Kinase Inhibitors: Cutting Edge Second Generation of Indirect Apoptogens

Table 7. World Market for Kinase Inhibitors (2010): Breakdown of Sales (In US$ Million) of Key Kinase Inhibitor Drugs (includes corresponding Graph/Chart)

Outlook

3.APOPTOSIS: A CONCEPTUAL OVERVIEW

Apoptosis: Definition
Importance of Apoptosis
Apoptosis Mechanism
Execution of Apoptosis
Dead Cell Removal
Apoptosis & Diseases
Faulty Apoptotic Pathways
Cancer
Non-Cancer Diseases
Neurodegeneration
Liver Diseases
Heart Diseases
Autoimmune Diseases
Categories of Apoptogens in the Marketplace
First Generation Indirect Apoptogens (IAs)
Second Generation Indirect Apoptogens (IAs)
Direct Apoptogens
How Apoptosis is Targeted in Disease Research…
Role of Death Receptors in Apoptosis
TNF Receptor Signaling
Signaling by Fas (CD95)
Apoptosis Induction by TRAIL
Caspase Inhibitors & Activators
Role of Intrinsic (Mitochondrial) Death Pathways in Apoptosis
Bcl-2 Family Proteins
Targeting Mitochondria Directly
Role of IAPs (inhibitors of apoptosis proteins) in Apoptosis Regulation
Tumor Suppressor p53

4.DRUG APPROVALS, INTRODUCTIONS AND CLINICAL TRIALS

Cleveland BioLabs Pre-Clinical Data Demonstrates Anticancer Effect of CBLB502
Senesco Technologies Files for IND for SNS01-T
Celgene Corporation Receives FDA approval for Priority Review of sNDA for ISTODAX®
IntelliCyt Introduces a Suite of Assay Kits for Apoptosis Screening
Vitamin E Tocotrienol Found to Increase Cancer Cell Apoptosis Without Toxicity
Protectan Technology May Lead to Drugs That Mitigate Effects of Radiation Exposure
VisEn Partners with MosaMedix to Introduce Annexin-Vivo 750 Imaging Agent for Monitoring Programmed Cell Death
AnaSpec Introduces Z-Fish Antibodies
Rexahn Pharmaceuticals Publishes Preclinical Research Data of Quinoxalinyl-Piperazine Compounds
Aegera Therapeutics Completes the Phase I Study of AEG35156/Sorafenib Combination
Amgen Announces Phase II Results of Clinical Studies of AMG 479
ArQule Announces Commencement of Phase II trial of ARQ 197 by Kyowa Hakko Kirin
ArQule Announces Daiichi Sankyo Plans to Move Ahead with Phase III clinical trial of ARQ 197
Celgene International Releases the Phase II Trial Data of ISTODAX® in Treatment of PTCL
Romidepsin (FK228/depsipeptide) Successfully completes Phase I clinical Trial
S*BIO Announces Results of Phase I trial for SB939 for Hematologic Malignancies
EntreMed Publishes the Phase II Pre Clinical Results of ENMD-2076
Eli Lilly Concludes Phases II trials for LY2181308 in Myeloid Leukaemia
Abbott to Present Data On Four Investigational Compounds
Can-Fite BioPharma to Commence the Phase I/II Clinical Trial with CF102
TetraLogic Announces Inclusion of Pfizer Ventures into the Series C Investors Syndicate
DiaTech Oncology Files Patent for MiCK (Microculture Kinetic) Assay
Gloucester Pharma Intends to Discuss About New Drug Application for Romidepsin
Cleveland BioLabs, Inc. Receives First Patent In the US
Daiichi Sankyo Commences Phase II Clinical Trials of CS-1008

5.RECENT INDUSTRY ACTIVITY

Cephalon to Take Over Gemin X
Amarantus BioSciences Enters into Licensing Agreement with Generex Biotechnology
Celgene Takes Over Gloucester Pharmaceuticals
Sanofi Signs Research and Development Agreement with Ascenta
BIOCIUS Life Sciences Collaborates with BlueSky Biotech for Providing Validated Enzymes
Ascenta Therapeutics Signs Agreement with Leukemia & Lymphoma Society
Ascenta Therapeutics Collaborates with Ascentage Pharma Group
Aposense and Roche Ink Collaboration Agreement
Conatus Takes Over Idun
Cancer Research Technology Enters into Licensing Deal with ValiRx
Scancell Holdings Signs Licensing Agreement with University of Nottingham
D-Pharm Collaborates with Wanbang Biopharmaceuticals
ACEA Biosciences, Roche and Vivo Biosciences Enter into Collaboration
Infinity and Mundipharma Enter Into Global Alliance
Sigma-Aldrich and Highlands Stable Isotope Corporation Enter into an Agreement
EntreMed, Inc. Enters Into Security Purchase Agreement with Group of Strategic Investors
IBA Signs Collaboration Agreement with Aposense
Clinical Data and CombinatoRx Sign Partnership and Licensing Agreement
FASgen and Centocor Ink Research and License Agreement
Graceway Pharmaceuticals Obtains Global Rights for GS 9191 Molecule
?terna Zentaris Signs an Agreement with Sanofi-Aventis

6.FOCUS ON SELECT PLAYERS

Abbott Laboratories (USA)
AbGenomics International, Inc. (USA)
Aegera Therapeutics, Inc. (Canada)
Amgen, Inc. (USA)
Anavex Life Sciences Corporation (USA)
ApopLogic Pharmaceuticals Inc. (USA)
Ascenta Therapeutics (USA)
ArQule, Inc. (USA)
Bioniche Life Sciences, Inc. (Canada)
Celgene Corporation (USA)
Chroma Therapeutics Ltd (UK)
Cancer Research Technology Ltd. (UK)
EntreMed, Inc. (USA)
EpiCept Corporation (USA)
Exelixis Inc. (USA)
Genextra S.p.A. (Italy)
Genta, Inc. (USA)
Infinity Pharmaceuticals Inc. (USA)
ISIS Pharmaceutical Inc. (USA)
Novartis Ltd. (Switzerland)
Pfizer, Inc. (USA)
Pharmacyclics, Inc. (USA)
S*BIO Pte Ltd. (Singapore)
Theraptosis SA (France)
TopoTarget A/S (Denmark)
Xigen SA (Switzerland)
?terna Zentaris GmbH (Germany)

7.GLOBAL MARKET PERSPECTIVE

Table 8. World Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 9. World Historic Review for Apoptosis Modulators in Oncology by Region/Country – Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

8.THE UNITED STATES

A. MARKET ANALYSIS

Current & Future Analysis
Overview
High Incidence of Pancreatic Cancer Drives Demand for Apoptosis Modulators in US Market
Drug Approvals, Introductions & Clinical Trials
Recent Industry Activity
Key Players

B. MARKET ANALYTICS

Table 10. US Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 11. US Historic Review for Apoptosis Modulators in Oncology – Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

9.CANADA

A. MARKET ANALYSIS

Current & Future Analysis
Clinical Trials
Recent Industry Activity
Key Players

B. MARKET ANALYTICS

Table 12. Canadian Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 13. Canadian Historic Review for Apoptosis Modulators in Oncology – Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

10.EUROPE

A. MARKET ANALYSIS

Current & Future Analysis
Clinical Trials

B. MARKET ANALYTICS

Table 14. European Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology by Region/Country – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 15. European Historic Review for Apoptosis Modulators in Oncology by Region/Country – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 16. European 15-Year Perspective For Apoptosis Modulators in Oncology by Region/Country – Percentage Breakdown of Revenue for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2003, 2010 and 2017 (includes corresponding Graph/Chart)

10A.FRANCE

A. MARKET ANALYSIS

Current & Future Analysis
Theraptosis SA – A Key French Player

B. MARKET ANALYTICS

Table 17. French Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 18. French Historic Review for Apoptosis Modulators in Oncology – Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

10B.GERMANY

A. MARKET ANALYSIS

Current & Future Analysis
?terna Zentaris GmbH - A Key German Player

B. MARKET ANALYTICS

Table 19. German Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 20. German Historic Review for Apoptosis Modulators in Oncology – Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

10C.ITALY

A. MARKET ANALYSIS

Current & Future Analysis
Genextra S.p.A. – A Key Italian Player

B. MARKET ANALYTICS

Table 21. Italian Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 22. Italian Historic Review for Apoptosis Modulators in Oncology – Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

10D.THE UNITED KINGDOM

A. MARKET ANALYSIS

Current & Future Analysis
Recent Industry Activity
Key Players

B. MARKET ANALYTICS

Table 23. UK Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 24. UK Historic Review for Apoptosis Modulators in Oncology – Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

10E.SPAIN

Market Analysis

Table 25. Spanish Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 26. Spanish Historic Review for Apoptosis Modulators in Oncology – Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

10F.REST OF EUROPE

A. MARKET ANALYSIS

Current & Future Analysis
Key Players

B. MARKET ANALYTICS

Table 27. Rest of Europe Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 28. Rest of Europe Historic Review for Apoptosis Modulators in Oncology – Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

11.ASIA-PACIFIC

A. MARKET ANALYSIS

Current & Future Analysis
Clinical Trials
Recent Industry Activity
Key Player

B. MARKET ANALYTICS

Table 29. Asia-Pacific Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 30. Asia-Pacific Historic Review for Apoptosis Modulators in Oncology – Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

12.LATIN AMERICA

A. MARKET ANALYSIS

Current & Future Analysis
Recent Industry Activity

B. MARKET ANALYTICS

Table 31. Latin America Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 32. Latin America Historic Review for Apoptosis Modulators in Oncology – Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

13.REST OF WORLD

A. MARKET ANALYSIS

Current & Future Analysis
Clinical Trials
Recent Industry Activity

B. MARKET ANALYTICS

Table 33. Rest of World Recent Past, Current and Future Analysis for Apoptosis Modulators in Oncology - Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 34. Rest of World Historic Review for Apoptosis Modulators in Oncology – Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Total Companies Profiled: 114 (including Divisions/Subsidiaries - 123)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle East